Twitter

Posts Tagged ‘rituximab’


MD Anderson researchers find that drug combination acts against aggressive chronic lymphocytic leukemia

A two-prong approach combining ibrutinib and rituximab (Rituxin) to treat aggressive chronic lymphocytic leukemia (CLL) produced responses with minor side effects in a Phase 2 clinical trial at The University of Texas MD Anderson Cancer Center.

Read More...

Cancer Treatment Could Help Against "Aggressive" Leukemia

A new study has found that combining ibrutinib and rituximab could help cancer patients with chronic lymphocytic leukemia .

Read More...

131I-rituximab for Relapsed or Refractory Marginal Zone B-cell Lymphoma

Condition :   Relapsed or Refractory Marginal Zone B-cell Lymphoma Intervention :   Drug: 131I-rituximab Sponsors :   Korea Cancer Center Hospital;   Korea Cancer Center Hospital Recruiting – verified August 2012

Read More...

Trial of FFP+HDMP+Rituximab for Ultra-high Risk Chronic Lymphocytic Leukemia

Condition :   Chronic Lymphocytic Leukemia Intervention :   Drug: FFP+HDMP+Rituximab Sponsors :   Jiangsu Province Hospital;   Jiangsu Province Hospital Recruiting – verified August 2012

Read More...

Rituximab or Zevalin – Efficacy Trial of Therapeutic Alternatives (RoZetta)

Condition :   Follicular Lymphoma Interventions :   Drug: Zevalin;   Drug: Rituximab Sponsors :   Spectrum Pharmaceuticals, Inc;   Spectrum Pharmaceuticals, Inc Not yet recruiting – verified August 2012

Read More...

A Study of Dinaciclib in Combination With Rituximab in Participants With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (P07974)

Conditions :   Chronic Lymphocytic Leukemia;   Small Lymphoctyic Lymphoma Interventions :   Drug: Dinaciclib;   Biological: Rituximab Sponsors :   Merck;   Merck Not yet recruiting – verified July 2012

Read More...

A Study of Subcutaneous Versus Intravenous MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in Patients With Previously Untreated CD20-Positive Diffuse Large B-Cell Lymphoma

Condition :   Lymphoma, B-Cell Interventions :   Drug: rituximab [MabThera/Rituxan];   Drug: rituximab [MabThera/Rituxan];   Drug: CHOP Sponsors :   Hoffmann-La Roche;   Hoffmann-La Roche Not yet recruiting – verified July 2012

Read More...

Lenalidomide, Rituximab, and PI3K Delta Inhibitor CAL-101 in Treating Patients With Recurrent Follicular Non-Hodgkin Lymphoma

Condition :   Lymphoma Interventions :   Biological: rituximab;   Drug: PI3K delta inhibitor CAL-101;   Drug: lenalidomide Sponsors :   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   National Cancer Institute (NCI) Not yet recruiting – verified July 2012

Read More...

Combination Chemotherapy With or Without Rituximab in Treating Younger Patients With Stage III-IV Non-Hodgkin Lymphoma or B-Cell Acute Leukemia

Conditions :   Leukemia;   Lymphoma Interventions :   Biological: rituximab;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: hydrocortisone sodium succinate;   Drug: leucovorin calcium;   Drug: methotrexate;   Drug: methylprednisolone;   Drug: prednisone;   Drug: vincristine sulfate Sponsors :   National Cancer Institute (NCI);   Children’s Oncology Group;   National Cancer Institute (NCI) Not yet recruiting – verified May 2012

Read More...

Combination of Oral Fludarabine, Mitoxantrone Und Rituximab Induction Therapy and Rituximab Maintenance Therapy in Follicular B-Cell Lymphoma

Conditions :   Follicular T-NHL Lymphoma;   Rituximab Maintenance Intervention :   Drug: Rituximab Sponsor :   Arbeitsgemeinschaft medikamentoese Tumortherapie Completed – verified March 2012

Read More...